Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus
Background: Hypertension is a common co-morbidity in patients with type 2 diabetes mellitus, and well tolerated, effective therapies are needed to achieve guideline-recommended blood pressure (BP) goals in these patients.
Objective: The aim of this study was to present the results of a prespecified analysis of key secondary endpoints from a 12-week, open-label, single-arm study evaluating the efficacy and safety of olmesartan medoxomil plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes.
Study Design and Methods: After a placebo run-in period, 192 patients received olmesartan medoxomil 20mg/day for 3 weeks. If BP remained ≥120/70mmHg, patients were uptitrated at 3-week intervals to olmesartanmedoxomil 40mg/day, olmesartan medoxomil/HCTZ 40/12.5mg/day, and olmesartan medoxomil/HCTZ 40/25mg/day.
Main Outcome Measure: Endpoints evaluated in this analysis were the change from baseline in mean seated cuff BP (SeBP), proportions of patients achieving SeBP goals, and distribution of SeBP reductions.
Results: Mean SeBP was 158.1/90.0mmHg at baseline. The mean±standard error of BP reductions at 12 weeks for systolic and diastolic BP were 21.3±1.1mmHg and 9.8±0.6 mmHg, respectively (p<0.0001 for each). At the end of the study, the proportion of patients with diabetes achieving the recommended SeBP goal of <130/80 mmHg was 41.1%.
Conclusions: An olmesartan medoxomil±HCTZ treatment regimen significantly reduced BP from baseline in patients with hypertension and type 2 diabetes.
Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00403481
- Wong ND, Lopez VA, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 2007 Dec 10; 167 (22): 2431–6 CrossRef
- Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903–13 CrossRef
- Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S65–7
- Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 412–9 CrossRef
- American Diabetes Association. Standards of medical care in diabetes — 2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13–61 CrossRef
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206–52 CrossRef
- Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105–87 CrossRef
- Sega R, Cesana G, Milesi C, et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997 Jul; 30 (1 Pt 1): 1–6 CrossRef
- Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003 Jun 12; 348 (24): 2407–15 CrossRef
- Okano Y, Tochikubo O, Umemura S. Relationship between base blood pressure during sleep and health-related quality of life in healthy adults. J Hum Hypertens 2007 Feb; 21 (2): 135–40 CrossRef
- Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006 Jun 1; 354 (22): 2368–74 CrossRef
- Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb 1; 65 (3): 209–18 CrossRef
- Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010 Mar; 26 (3): 721–8 CrossRef
- National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007 Feb; 49 (2 Suppl. 2): S12–154
- Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med 2007 Aug; 120 (8): 713–9 CrossRef
- Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007 Jun; 64 (12): 1279–83 CrossRef
- Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) 2008 Sep; 10 (9): 707–13; discussion 714–5 CrossRef
- Tofe Povedano S, Garcia De La Villa B. 24-Hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich) 2009 Aug; 11 (8): 426–31 CrossRef
- Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol 2008 Mar; 18 (3): 222–9 CrossRef
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352 (9131): 837–53 CrossRef
- UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 Sep 12; 317 (7160): 703–13 CrossRef
- Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 Feb; 16 (2): 434–44 CrossRef
- Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 Dec 4; 288 (21): 2709–16 CrossRef
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755–62 CrossRef
- Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007; 6: 28 CrossRef
- Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006 Jul; 8 (7): 470–80 CrossRef
- Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Drugs in R & D
Volume 11, Issue 3 , pp 251-257
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors